HC Wainwright Rates Relmada Therapeutics (RLMD) buy

HC Wainwright reaffirms its positive outlook on RLMD with a $12 price target, a 81.82% upside from the current price.

By EarningsIQ Research Desk · Published Jun 18, 2026, 7:02 AM EDT · Updated Jun 19, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Relmada Therapeutics, Inc. ($RLMD) "buy" with a $12 price target on June 18, 2026.

Since the rating, $RLMD is down 4.2% after 1 week, down 25.7% after 1 month and down 53.9% to date (from the $6.73 close on Jun 18, 2026).

RLMD Relmada Therapeutics, Inc.

$3.10 -29.06% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating on RLMD on June 18, 2026, with a price target of $12.
HC Wainwright's $12 price target implies 81.82% upside from Relmada Therapeutics, Inc.'s ($RLMD) current $6.60 share price.
RLMD shares traded around $6.6, with recent insider buying activity from top executives.
Peers like Janus Henderson and OrbiMed Advisors have significantly increased their holdings in RLMD.

Get $RLMD trade alerts by text

We text you when insiders, Congress or big funds trade $RLMD. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Relmada Therapeutics, Inc. alert may contain errors. Disclosures

HC Wainwright & Co. reiterated its buy rating on RLMD on June 18, 2026, setting a price target of $12. This move comes as the stock trades around $6.6, reflecting confidence in RLMD's future prospects.

Other Institutional Activity in RLMD

Several institutional investors have been active in RLMD recently. Janus Henderson Group PLC increased its holdings by 3,793,862 shares, reaching a total of 11,063,862 shares valued at approximately $76.89 million. Squadron Capital Management LLC added 1,774,571 shares, bringing its total to 8,474,571 shares worth about $58.98 million. Spruce Street Capital LP also boosted its stake by 2,175,933 shares, ending with 6,262,114 shares valued at $42.99 million. OrbiMed Advisors LLC made a significant addition, increasing its holdings by 2,105,264 shares, bringing their total to 4,715,864 shares worth $32.82 million.

Relmada Therapeutics, Inc. Stock Up 60.2%

Shares of RLMD are currently trading around $6.6. The stock has attracted attention from both analysts and institutional investors, suggesting a positive outlook despite its current trading price.

12-month forecast

$RLMD price target

Relmada Therapeutics, Inc. daily closes and this analyst's $12 target. Not advice.

Insider Buying and Selling at Relmada Therapeutics, Inc.

There has been notable insider buying at RLMD. On December 15, 2025, both CFO Maged Shenouda and CEO Sergio Traversa purchased 11,665 and 27,500 shares, respectively, at an average price of $4.12. Additionally, on December 12, 2025, COO Paul Edward Kelly acquired 828,000 shares, while John Glasspool bought 164,000 shares, although the price for these transactions was not specified.

Analysts Set New Price Targets

On June 18, 2026, HC Wainwright & Co. reiterated its buy rating on RLMD with a $12 price target. Piper Sandler also initiated coverage with a buy rating and a $12 target on March 24, 2026. Mizuho maintained its buy rating on March 20, 2026, setting a higher target of $19. The consensus among analysts is generally positive, with a mean target price reflecting optimism for RLMD's potential.

About RLMD

RLMD is a company focused on advancing innovative therapies. It operates in a dynamic sector that requires continuous research and development. The company's strategic initiatives aim to address unmet medical needs, positioning itself as a potential leader in its field.

Bottom Line

HC Wainwright's reiteration of its buy rating and $12 price target underscores a positive sentiment towards RLMD. Institutional investors have shown increased interest, significantly boosting their holdings. While insider purchases suggest confidence from the company's leadership, it's important for investors to note that analyst ratings are based on projections and market conditions can change.